# Orelabrutinib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/orelabrutinib

> The next catalyst for orelabrutinib, sponsored by Zenas BioPharma, Inc. (ZBIO), is its primary completion, June 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | orelabrutinib |
| Codes | ZB020, ICP022 |
| Sponsor | Zenas BioPharma, Inc. (ZBIO) https://sec-api.dev/companies/zbio/catalysts |
| Indications | [secondary progressive multiple sclerosis](https://sec-api.dev/indications/secondary-progressive-multiple-sclerosis), [non-active secondary progressive multiple sclerosis](https://sec-api.dev/indications/non-active-secondary-progressive-multiple-sclerosis), non-active spms, secondary progressive ms, [Multiple Sclerosis (MS) Primary Progressive](https://sec-api.dev/indications/multiple-sclerosis-ms-primary-progressive) |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### Q1 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Secondary Progressive Multiple Sclerosis.
- First seen 2025-10-08, last confirmed 2026-03-30.
- SEC Form 8-K (accession 0001104659-25-102317): "The Company also expects to initiate a global Phase 3 trial of orelabrutinib in patients with Secondary Progressive Multiple Sclerosis ("SPMS") in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465925102317/tm2529508d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-102317): "Zenas also expects to initiate a global Phase 3 trial of orelabrutinib in patients with Secondary Progressive Multiple Sclerosis (SPMS) in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465925102317/tm2529508d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-097663): "Zenas plans to initiate a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib in patients with Secondary Progressive MS (SPMS) in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-1.htm
- SEC prospectus (424B) (accession 0001104659-26-036534): "In the first quarter of 2026, we plan to initiate a Phase 3 clinical trial evaluating orelabrutinib in patients with Secondary Progressive Multiple Sclerosis ("SPMS")." https://www.sec.gov/Archives/edgar/data/1953926/000110465926036534/tm261753-10_424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-036536): "In the first quarter of 2026, we plan to initiate a Phase 3 clinical trial evaluating orelabrutinib in patients with Secondary Progressive Multiple Sclerosis ("SPMS")." https://www.sec.gov/Archives/edgar/data/1953926/000110465926036536/tm261753-11_424b5.htm
- SEC Form 10-K (accession 0001104659-26-027964): "In the first quarter of 2026, we plan to initiate a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with non-active SPMS, with a primary endpoint of time to onset of 24-week CDP, and with a goal to report topline results in 2030." https://www.sec.gov/Archives/edgar/data/1953926/000110465926027964/zbio-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-027964): "In the first quarter of 2026, we plan to initiate a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with non-active SPMS, with a primary endpoint of time to onset of 24-week CDP." https://www.sec.gov/Archives/edgar/data/1953926/000110465926027964/zbio-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-109753): "In the first quarter of 2026, we plan to initiate a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with Secondary Progressive Multiple Sclerosis ("SPMS"), with a primary endpoint of time to onset of 24-week CDP." https://www.sec.gov/Archives/edgar/data/1953926/000110465925109753/zbio-20250930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-097663): "a Progressive MS franchise molecule A validated mechanism and potentially best - in - class profile in Phase 3 registration - directed trial for PPMS and initiating Phase 3 registrational trial for SPMS expected in 1Q 2026" https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-2.htm

### Mar 2026: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: non-active secondary progressive multiple sclerosis.
- First seen 2026-05-13, last confirmed 2026-11-06.
- SEC prospectus (424B) (accession 0001104659-26-123876): "In March of 2026, we initiated a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with non-active secondary progressive multiple sclerosis, with a primary endpoint of time to onset of 24-week CDP." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123876/tm2629107-1_424b5.htm
- SEC Form 10-Q (accession 0001104659-26-123040): "In March of 2026, we initiated a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with non-active secondary progressive multiple sclerosis ("naSPMS"), with a primary endpoint of time to onset of 24-week CDP." https://www.sec.gov/Archives/edgar/data/1953926/000110465926123040/zbio-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095448): "In March of 2026, we initiated a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with non-active secondary progressive multiple sclerosis ("naSPMS"), with a primary endpoint of time to onset of 24-week CDP." https://www.sec.gov/Archives/edgar/data/1953926/000110465926095448/zbio-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-059735): "In March of 2026, we initiated a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with non-active secondary progressive multiple sclerosis ("naSPMS"), with a primary endpoint of time to onset of 24-week CDP." https://www.sec.gov/Archives/edgar/data/1953926/000110465926059735/zbio-20260331x10q.htm

### June 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Multiple Sclerosis (MS) Primary Progressive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07067463 (A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." https://clinicaltrials.gov/study/NCT07067463

### Jun to Sep 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Multiple Sclerosis (MS) Primary Progressive.
- First seen 2025-10-08, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07067463 (A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." https://clinicaltrials.gov/study/NCT07067463
- SEC Form 10-K (accession 0001104659-26-027964): "The PriMroSe Trial is a global, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of orelabrutinib dosed 80 mg once daily QD compared to placebo in patients with PPMS, with a primary endpoint of time to onset of 12-week composite confirmed disability progression ("cCDP"), with a goal to report topline results in 2030." https://www.sec.gov/Archives/edgar/data/1953926/000110465926027964/zbio-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-097663): "The Phase 3 study is a global, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of orelabrutinib dosed 80 mg once daily QD compared to placebo in patients with PPMS, with a primary endpoint of time to onset of 12-week composite confirmed disability progression (cCDP), with a goal to report topline results in 2030." https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-3.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-097663): "Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with SPMS, with a primary endpoint of time to onset of 24-week CDP, with a goal to report topline results in 2030." https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-3.htm
- SEC Form 10-K (accession 0001104659-26-027964): "In the first quarter of 2026, we plan to initiate a second global, Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib dosed 80 mg QD compared to placebo in patients with non-active SPMS, with a primary endpoint of time to onset of 24-week CDP, and with a goal to report topline results in 2030." https://www.sec.gov/Archives/edgar/data/1953926/000110465926027964/zbio-20251231x10k.htm

### June 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Secondary Progressive Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07299019 (A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." https://clinicaltrials.gov/study/NCT07299019

### Jun to Sep 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Secondary Progressive Multiple Sclerosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07299019 (A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06 (ESTIMATED); Lead Sponsor Zenas BioPharma (USA), LLC." https://clinicaltrials.gov/study/NCT07299019

## Same indication

- [Foralumab](https://sec-api.dev/pdufa/foralumab) (TLSA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/orelabrutinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Orelabrutinib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/orelabrutinib

```bibtex
@misc{secapidev_pdufa_orelabrutinib_20261116,
  title        = {Orelabrutinib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/orelabrutinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_orelabrutinib_20261116","title":"Orelabrutinib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/orelabrutinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
